Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.

Erythropoiesis-stimulating agent (ESA) responsiveness has been reported to be associated with increased mortality in hemodialysis (HD) patients. ESA requirement to obtain the same hemoglobin (Hb) level is different between HD and peritoneal dialysis (PD) patients. In this study, we investigated the...

Full description

Bibliographic Details
Main Authors: Myoung Nam Bae, Su Hyun Kim, Young Ok Kim, Dong Chan Jin, Ho Chul Song, Euy Jin Choi, Yong-Lim Kim, Yon-Su Kim, Shin-Wook Kang, Nam-Ho Kim, Chul Woo Yang, Yong Kyun Kim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0143348
id doaj-f18e3ba2844140f6b6110cc8d1f4a0d7
record_format Article
spelling doaj-f18e3ba2844140f6b6110cc8d1f4a0d72021-03-03T19:57:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011011e014334810.1371/journal.pone.0143348Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.Myoung Nam BaeSu Hyun KimYoung Ok KimDong Chan JinHo Chul SongEuy Jin ChoiYong-Lim KimYon-Su KimShin-Wook KangNam-Ho KimChul Woo YangYong Kyun KimErythropoiesis-stimulating agent (ESA) responsiveness has been reported to be associated with increased mortality in hemodialysis (HD) patients. ESA requirement to obtain the same hemoglobin (Hb) level is different between HD and peritoneal dialysis (PD) patients. In this study, we investigated the impact of ESA responsiveness on mortality between both HD and PD patients. Prevalent HD and PD patients were selected from the Clinical Research Center registry for end-stage renal disease, a prospective cohort study in Korea. ESA responsiveness was estimated using an erythropoietin resistant index (ERI) (U/kg/week/g/dL). Patients were divided into three groups by tertiles of ERI. ESA responsiveness was also assessed based on a combination of ESA dosage and hemoglobin (Hb) levels. The primary outcome was all-cause mortality. A total of 1,594 HD and 876 PD patients were included. The median ESA dose and ERI were lower in PD patients compared with HD patients (ESA dose: 4000 U/week vs 6000 U/week, respectively. P<0.001, ERI: 7.0 vs 10.4 U/kg/week/g/dl, respectively. P<0.001). The median follow-up period was 40 months. In HD patients, the highest ERI tertile was significantly associated with higher risk for all-cause mortality (HR 1.96, 95% CI, 1.07 to 3.59, P = 0.029). HD patients with high-dose ESA and low Hb levels (ESA hypo-responsiveness) had a significantly higher risk of all-cause mortality (HR 2.24, 95% CI, 1.16 to 4.31, P = 0.016). In PD patients, there was no significant difference in all-cause mortality among the ERI groups (P = 0.247, log-rank test). ESA hypo-responsiveness was not associated with all-cause mortality (HR = 1.75, 95% CI, 0.58 to 5.28, P = 0.319). Our data showed that ESA hypo-responsiveness was associated with an increased risk of all-cause mortality in HD patients. However, in PD patients, ESA hypo-responsiveness was not related to all-cause mortality. These finding suggest the different prognostic value of ESA responsiveness between HD and PD patients.https://doi.org/10.1371/journal.pone.0143348
collection DOAJ
language English
format Article
sources DOAJ
author Myoung Nam Bae
Su Hyun Kim
Young Ok Kim
Dong Chan Jin
Ho Chul Song
Euy Jin Choi
Yong-Lim Kim
Yon-Su Kim
Shin-Wook Kang
Nam-Ho Kim
Chul Woo Yang
Yong Kyun Kim
spellingShingle Myoung Nam Bae
Su Hyun Kim
Young Ok Kim
Dong Chan Jin
Ho Chul Song
Euy Jin Choi
Yong-Lim Kim
Yon-Su Kim
Shin-Wook Kang
Nam-Ho Kim
Chul Woo Yang
Yong Kyun Kim
Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
PLoS ONE
author_facet Myoung Nam Bae
Su Hyun Kim
Young Ok Kim
Dong Chan Jin
Ho Chul Song
Euy Jin Choi
Yong-Lim Kim
Yon-Su Kim
Shin-Wook Kang
Nam-Ho Kim
Chul Woo Yang
Yong Kyun Kim
author_sort Myoung Nam Bae
title Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
title_short Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
title_full Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
title_fullStr Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
title_full_unstemmed Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
title_sort association of erythropoietin-stimulating agent responsiveness with mortality in hemodialysis and peritoneal dialysis patients.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Erythropoiesis-stimulating agent (ESA) responsiveness has been reported to be associated with increased mortality in hemodialysis (HD) patients. ESA requirement to obtain the same hemoglobin (Hb) level is different between HD and peritoneal dialysis (PD) patients. In this study, we investigated the impact of ESA responsiveness on mortality between both HD and PD patients. Prevalent HD and PD patients were selected from the Clinical Research Center registry for end-stage renal disease, a prospective cohort study in Korea. ESA responsiveness was estimated using an erythropoietin resistant index (ERI) (U/kg/week/g/dL). Patients were divided into three groups by tertiles of ERI. ESA responsiveness was also assessed based on a combination of ESA dosage and hemoglobin (Hb) levels. The primary outcome was all-cause mortality. A total of 1,594 HD and 876 PD patients were included. The median ESA dose and ERI were lower in PD patients compared with HD patients (ESA dose: 4000 U/week vs 6000 U/week, respectively. P<0.001, ERI: 7.0 vs 10.4 U/kg/week/g/dl, respectively. P<0.001). The median follow-up period was 40 months. In HD patients, the highest ERI tertile was significantly associated with higher risk for all-cause mortality (HR 1.96, 95% CI, 1.07 to 3.59, P = 0.029). HD patients with high-dose ESA and low Hb levels (ESA hypo-responsiveness) had a significantly higher risk of all-cause mortality (HR 2.24, 95% CI, 1.16 to 4.31, P = 0.016). In PD patients, there was no significant difference in all-cause mortality among the ERI groups (P = 0.247, log-rank test). ESA hypo-responsiveness was not associated with all-cause mortality (HR = 1.75, 95% CI, 0.58 to 5.28, P = 0.319). Our data showed that ESA hypo-responsiveness was associated with an increased risk of all-cause mortality in HD patients. However, in PD patients, ESA hypo-responsiveness was not related to all-cause mortality. These finding suggest the different prognostic value of ESA responsiveness between HD and PD patients.
url https://doi.org/10.1371/journal.pone.0143348
work_keys_str_mv AT myoungnambae associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT suhyunkim associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT youngokkim associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT dongchanjin associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT hochulsong associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT euyjinchoi associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT yonglimkim associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT yonsukim associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT shinwookkang associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT namhokim associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT chulwooyang associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
AT yongkyunkim associationoferythropoietinstimulatingagentresponsivenesswithmortalityinhemodialysisandperitonealdialysispatients
_version_ 1714824880491331584